RPh 201

Drug Profile

RPh 201

Alternative Names: RPh201

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regenera Pharma
  • Developer Hadassah Medical Organization; Regenera Pharma
  • Class Antidementias; Herbal medicines
  • Mechanism of Action G protein-coupled receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Optic nerve disorders
  • Phase I/II Alzheimer's disease
  • No development reported Persistent vegetative state
  • Discontinued Chronic wounds

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Persistent-vegetative-state in Israel (SC, Injection)
  • 01 Dec 2016 Regenera completes a phase II trial for Optic nerve disorders in Israel (NCT02045212)
  • 30 Aug 2015 RPh 201 is still in phase I trials for Persistent vegetative state in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top